EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection

Duc Minh Nguyen, Cristina Poveda, Jeroen Pollet, Fabian Gusovsky, Maria Elena Bottazzi, Peter J Hotez, Kathryn Marie Jones iD

PLOS Neglected Tropical Diseases · 2023

DOI: 10.1371/journal.pntd.0011519 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2023. Verfasst von Duc Minh Nguyen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Comparative Medicine, Baylor College of Medicine, Houston, Texas, United States of America. Hauptthemen laut MEDLINE: Chagas Disease, Trypanosoma cruzi, Vaccines, Nitroimidazoles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Southern Star Medical Research Institute, The Pathology and Histology Core at Baylor College of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chagas disease, chronic infection with Trypanosoma cruzi , mainly manifests as cardiac disease. However, the liver is important for both controlling parasite burdens and metabolizing drugs. Notably, high doses of anti-parasitic drug benznidazole (BNZ) causes liver damage. We previously showed that combining low dose BNZ with a prototype therapeutic vaccine is a dose sparing strategy that effectively reduced T . cruzi induced cardiac damage. However, the impact of this treatment on liver health is unknown. Therefore, we evaluated several markers of liver health after treatment with low dose BNZ plus the vaccine therapy in comparison to a curative dose of BNZ. Methodology Female BALB/c mice were infected with a bioluminescent T . cruzi H1 clone for approximately 70 days, then randomly divided into groups of 15 mice each. Mice were treated with a 25mg/kg BNZ, 25μg Tc24-C4 protein/ 5μg E6020-SE (Vaccine), 25mg/kg BNZ followed by vaccine, or 100mg/kg BNZ (curative dose). At study endpoints we evaluated hepatomegaly, parasite burden by quantitative PCR, cellular infiltration by histology, and expression of B-cell translocation gene 2(BTG2) and Peroxisome proliferator-activated receptor alpha (PPARα) by RT-PCR. Levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) were quantified from serum.

Results

Curative BNZ treatment significantly reduced hepatomegaly, liver parasite burdens, and the quantity of cellular infiltrate, but significantly elevated serum levels of ALT, AST, and LDH. Low BNZ plus vaccine did not significantly affect hepatomegaly, parasite burdens or the quantity of cellular infiltrate, but only elevated ALT and AST. Low dose BNZ significantly decreased expression of both BTG2 and PPARα, and curative BNZ reduced expression of BTG2 while low BNZ plus vaccine had no impact.

Conclusions

These data confirm toxicity associated with curative doses of BNZ and suggest that while dose sparing low BNZ plus vaccine treatment does not reduce parasite burdens, it better preserves liver health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chagas DiseaseTrypanosoma cruziVaccinesNitroimidazolesTrypanocidal AgentsFemaleAnimalsMiceHepatomegalyPersistent InfectionPPAR alpha

Substanzen

PPAR alphaVaccinesNitroimidazolesTrypanocidal Agents

Autor:innen und Institutionen

  • Center for Comparative Medicine, Baylor College of Medicine, Houston, Texas, United States of America.
  • Texas Children's Hospital Center for Vaccine Development, Department of Pediatrics, Division of Tropical Medicine, Baylor College of Medicine, Houston, Texas, United States of America.
  • Global Health Research, Eisai, Inc., Cambridge, Massachusetts, United States of America.
  • Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, United States of America.
  • Department of Biology, Baylor University, Waco, Texas, United States of America.
  • James A. Baker III Institute for Public Policy, Rice University, Houston, Texas, United States of America.

ORCID-Profile: Kathryn Marie Jones

Förderung

  • NCI NIH HHS
  • Southern Star Medical Research Institute
  • The Pathology and Histology Core at Baylor College of Medicine

Zitieren

APA

Nguyen, D. M., Poveda, C., Pollet, J., Gusovsky, F., Bottazzi, M. E., Hotez, P. J., & Jones, K. M. (2023). The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0011519

Vancouver

Nguyen DM, Poveda C, Pollet J, Gusovsky F, Bottazzi ME, Hotez PJ, et al. The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection. PLOS Neglected Tropical Diseases. 2023. doi:10.1371/journal.pntd.0011519

BibTeX
@article{Nguyen2023,
  author = {Nguyen, Duc Minh and Poveda, Cristina and Pollet, Jeroen and Gusovsky, Fabian and Bottazzi, Maria Elena and Hotez, Peter J and Jones, Kathryn Marie},
  title = {The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2023},
  doi = {10.1371/journal.pntd.0011519}
}
Kostenlos starten →